Noncoding regions are the main source of targetable tumor-specific antigens
- PMID: 30518613
- DOI: 10.1126/scitranslmed.aau5516
Noncoding regions are the main source of targetable tumor-specific antigens
Abstract
Tumor-specific antigens (TSAs) represent ideal targets for cancer immunotherapy, but few have been identified thus far. We therefore developed a proteogenomic approach to enable the high-throughput discovery of TSAs coded by potentially all genomic regions. In two murine cancer cell lines and seven human primary tumors, we identified a total of 40 TSAs, about 90% of which derived from allegedly noncoding regions and would have been missed by standard exome-based approaches. Moreover, most of these TSAs derived from nonmutated yet aberrantly expressed transcripts (such as endogenous retroelements) that could be shared by multiple tumor types. Last, we demonstrated that, in mice, the strength of antitumor responses after TSA vaccination was influenced by two parameters that can be estimated in humans and could serve for TSA prioritization in clinical studies: TSA expression and the frequency of TSA-responsive T cells in the preimmune repertoire. In conclusion, the strategy reported herein could considerably facilitate the identification and prioritization of actionable human TSAs.
Copyright © 2018 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.
Comment in
-
Expanding the search.Nat Rev Cancer. 2019 Mar;19(3):126-127. doi: 10.1038/s41568-018-0101-9. Nat Rev Cancer. 2019. PMID: 30617268 No abstract available.
Similar articles
-
Proteogenomics Uncovers a Vast Repertoire of Shared Tumor-Specific Antigens in Ovarian Cancer.Cancer Immunol Res. 2020 Apr;8(4):544-555. doi: 10.1158/2326-6066.CIR-19-0541. Epub 2020 Feb 11. Cancer Immunol Res. 2020. PMID: 32047025
-
A Roadmap Toward the Definition of Actionable Tumor-Specific Antigens.Front Immunol. 2020 Dec 3;11:583287. doi: 10.3389/fimmu.2020.583287. eCollection 2020. Front Immunol. 2020. PMID: 33424836 Free PMC article. Review.
-
Genome-scale search of tumor-specific antigens by collective analysis of mutations, expressions and T-cell recognition.Mol Immunol. 2009 May;46(8-9):1824-9. doi: 10.1016/j.molimm.2009.01.019. Epub 2009 Feb 24. Mol Immunol. 2009. PMID: 19243822
-
Proteogenomic discovery of cancer antigens: Neoantigens and beyond.Pathol Int. 2019 Sep;69(9):511-518. doi: 10.1111/pin.12841. Epub 2019 Aug 9. Pathol Int. 2019. PMID: 31397525 Review.
-
Alternative tumour-specific antigens.Nat Rev Cancer. 2019 Aug;19(8):465-478. doi: 10.1038/s41568-019-0162-4. Epub 2019 Jul 5. Nat Rev Cancer. 2019. PMID: 31278396 Free PMC article. Review.
Cited by
-
Upstream open reading frames: new players in the landscape of cancer gene regulation.NAR Cancer. 2024 May 20;6(2):zcae023. doi: 10.1093/narcan/zcae023. eCollection 2024 Jun. NAR Cancer. 2024. PMID: 38774471 Free PMC article. Review.
-
Evaluation of the antitumor effect of neoantigen peptide vaccines derived from the translatome of lung cancer.Cancer Immunol Immunother. 2024 May 14;73(7):129. doi: 10.1007/s00262-024-03670-0. Cancer Immunol Immunother. 2024. PMID: 38744688 Free PMC article.
-
Tumor Antigens beyond the Human Exome.Int J Mol Sci. 2024 Apr 25;25(9):4673. doi: 10.3390/ijms25094673. Int J Mol Sci. 2024. PMID: 38731892 Free PMC article. Review.
-
Single-cell sequencing of tumour infiltrating T cells efficiently identifies tumour-specific T cell receptors based on the T cell activation score.Cancer Immunol Immunother. 2024 May 10;73(7):123. doi: 10.1007/s00262-024-03710-9. Cancer Immunol Immunother. 2024. PMID: 38727812 Free PMC article.
-
Transposable elements regulate thymus development and function.Elife. 2024 Apr 18;12:RP91037. doi: 10.7554/eLife.91037. Elife. 2024. PMID: 38635416 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials